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Type 2 diabetes is characterized by hyperglycemia resulting from insulin resistance in the setting of inadequate beta-cell
compensation. Recent studies indicate that for attaining a well-functioning ß-cell mass, parathyroid hormone-related protein
(PTHrP) is a very promising candidate among several insulinotropic peptides. In order to elucidate its role, we determine the
levels of PTHrP, insulin and c-peptide in type 2 diabetics and in normal subjects in the fasting state. We enrolled 28 patients (16
men and 12 postmenopausal women) with type 2 diabetes and twenty eight aged-matched healthy individuals as control subjects
(15 men and 13 women). PTHrP was statistically signiﬁcant correlated with glucose in type 2 diabetes and in normal subjects in
the fasting state. Additionally, PTHrP serum levels exhibited a signiﬁcant increase in type 2 diabetes compared to control subjects.
Interestingly, PTHrP showed a positive correlation with insulin levels only among healthy individuals presumably due to defective
glucose stimulated insulin secretion known to occur in type 2 diabetics. In conclusion, the strong positive relation of PTHrP with
glucose in the fasting state in patients with type 2 diabetes mellitus raises several questions for further experimentation concerning
its exact role and physiological signiﬁcance.
Copyright © 2009 I. Legakis and T. Mantouridis. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Blood glucose homeostasis is controlled by the endocrine
cells of the pancreas, located in the islets of Langerhans. The
islet cells monitor the concentration of glucose in the blood
and secrete hormones with opposite eﬀects. Failure of ß-cell
survival is critical to the etiology of diabetes mellitus as well
as in the setting of islet transplantation [1, 2].
Recently a large number of factors controlling the
diﬀerentiation of beta-cells have been identiﬁed. They are
classiﬁed into the following main categories: growth factors,
cytokine and inﬂammatory factors, and hormones, such as
PTH-related peptide (PTHrP) and glucagon-like peptide-
1( G L P - 1 )[ 3–5]. Indeed, mice with PTHrP overexpression
under the control of the rat insulin gene promoter derive
their increases in ß-cell number and overall islet mass, not
as a result of an increase in b-cell proliferation but from a
prolongationofß-cellsurvival[5].Ingeneral,treatmentwith
these external stimuli can restore a functional beta-cell mass
in diabetic animals, but further studies are required before it
can be applied to humans.
In that respect, the recognition that PTHrP overexpres-
sion enhances ß-cell survival shows potential therapeutic
targets for pharmaceutical agents aimed at improving the
survivalofß-cellsindiabetes[6].Asanattempttoinvestigate
the role of PTHrP in diabetes, we performed serum determi-
nations of PTHrP, insulin, and c-peptide in type 2 diabetics
and in normal subjects in the fasting state.
2.MaterialsandMethods
We enrolled 28 patients with type 2 diabetes (HbA1c
7.18 ± : 0.5%) 16 men (aged 56.8 ± 2.4 years, BMI
29 ± 1.9kg/m2) and 12 postmenopausal women (follicle-
stimulating hormone(FSH)>30mIU/mL,aged58 ±2years,
BMI 29 ± 1.7kg/m2) with a maximum disease duration
of 4 years. Twenty-eight healthy individuals participated in
the study as control subjects: 15 men (aged 57.3 ± 1.3 years,
BMI 27.7 ± 1.09kg/m2) and 13 women (FSH >30 mIU/mL,
aged 56.84 ± 1.8years, BMI 27.46 ± 1.3kg/m2)w i t hn o
history of diabetes, hypertension, liver, or kidney disease.2 Experimental Diabetes Research
Table 1: Summary of glucose, PTH-related protein, C-peptide, and
insulin levels in males and females by health status (healthy or
diabetics).
Female Male
Median (IQR)
∗ Median (IQR)
Diabetes
Glucose (mg/dL) 146.5 (138.0, 198.0) 169.0 (150.5, 196.0)
PTH-related protein
(pg/mL)
300.0 (265.0, 555.0) 430.0 (320.0, 550.0)
C-peptide (ng/mL) 2.28 (1.87, 3.38) 2.44 (1.84, 3.62)
Insulin (μIU/L) 7.35 (4.80, 11.95) 10.71 (5.75, 17.08)
Normal
Glucose (mg/dL) 89.0 (85.0, 97.0) 98.0 (85.0, 106.0)
PTH-related protein
(pg/mL)
180.0 (170.0, 190.0) 190.0 (180.0, 200.0)
C-peptide (ng/mL) 2.22 (2.00, 3.70) 2.13 (1.86, 2.78)
Insulin (μIU/L) 7.13 (4.88, 9.13) 8.20 (6.39, 10.99)
∗Interquartile range.
None of the nondiabetic healthy volunteers were taking any
medication, and none had a ﬁrst degree relative with type 2
diabetes.
Written informed consent was obtained from all study
participants. Blood samples were collected at rest at 8:00
A.M., after an overnight fast and 24-hour alcohol absten-
tion. PTHrP was determined in serum by a competitive
enzyme immunoassay (Peninsula Laboratories, Belmont,
CA). Insulin was measured in serum by an enzyme-linked
immunosorbent assay (A×SYM; Abbott Laboratories, North
Chicago,IL).Atwo-sitesandwichimmunoassay,usingdirect
chemiluminescent technology (ADVIA Centaur; Bayer, Lev-
erkusen,Germany),wasusedforthedeterminationofserum
C-peptide. Statistical evaluation of the results was performed
using multivariate median regression models. Statistical
signiﬁcance was set at P<. 05. Conﬁdence intervals (CI) are
reported at 95%.
3. Results
According to our data, a statistical signiﬁcant increase was
detected in both PTHrP and glucose levels in women and
men with type 2 diabetes compared with control subjects.
In particular, PTHrP serum levels showed a signiﬁcant (P<
.001) correlation between sex and health status. The esti-
mated diﬀerence for health status (diabetics versus healthy)
on median PTH-related protein levels was 130pg/mL (95%
CI: 92–168, P<. 001) among male individuals and
230pg/mL (95% CI: 196–264, P<. 001) among female
individuals (after adjusting for diﬀerences of health status).
The estimated diﬀerence for sex (male versus female)
on median PTH-related protein levels was 10pg/mL (95%
CI: −24–44, P = .562) among healthy individuals (non-
signiﬁcant) and 110pg/mL (95% CI: 72–148, P<. 001)
among diabetics (after adjusting for diﬀerences by health
status, Table 1).
Table 2: Correlation coeﬃcients (Spearman’s Rho, P-values in
italics) between glucose, PTH-related protein, C-peptide, and
insulin (by sex) in diabetics.
Glucose PTH-related protein C-peptide
RR R
PP P
Female
PTH-related protein 0.9732
<.0001
C-peptide 0.1781 0.1528
.3942 .4658
Insulin 0.1697 0.1594 0.8671
.4173 .4465 <.0001
Male
PTH-related protein 0.9905
<.0001
C-peptide 0.2078 0.1787
.2621 .3361
Insulin 0.3035 0.2949 0.8246
.0970 .1073 <.0001
Table 3: Correlation coeﬃcients (Spearman’s Rho, P-values in
italics) between Glucose, PTH-related protein, C-peptide, and
insulin (by health status).
Glucose PTH-related protein C-peptide
RR R
PP P
Diabetics
PTH-related protein 0.9922
<.0001
C-peptide 0.1176 0.1083
.5512 .5833
Insulin 0.0385 0.0371 0.8692
.8459 .8511 <.0001
Healthy
PTH-related protein 0.9080
<.0001
C-peptide 0.3454 0.3095
.0718 .1090
Insulin 0.5095 0.4937 0.7378
.0056 .0076 <.0001
Performing Spearman correlation coeﬃcient analy-
sis, positive and statistically signiﬁcant correlations were
detected between (a) glucose and PTHrP and (b) c-peptide
and insulin. These positive associations were slightly more
pronounced among diabetics. There was no diﬀerence in
the strength of these associations between men and women
(Table 2). Interestingly, PTHrP showed a positive correlation
with insulin levels only among healthy individuals presum-
ably due to defective glucose stimulated insulin secretion
known to occur in type 2 diabetics (Table 3).Experimental Diabetes Research 3
4. Discussion
Type 2 diabetes is characterized by hyperglycemia resulting
from insulin resistance in the setting of inadequate ß-
cell compensation. Impaired ß-cell function and possibly
beta-cell mass appear to be reversible, particularly at early
stages of the disease. Despite an enormous increase in our
understandingofisletdiﬀerentiationanddevelopment,there
is sparse information regarding the factors and pathways
that regulate growth, survival, and death of islet cells.
Nevertheless, in recent years, a large number of factors
controlling the diﬀerentiation of ß-cells have been identiﬁed,
and among them the PTHrP emerged as a strong candidate
in ß-cell survival.
Ishida et al. [7] reported that type 2 diabetics exhibited
higher serum PTHrP levels than control subjects. However,
in that study no stimulation tests were done to demonstrate
whether PTHrP is released from the pancreas in response
to insulin secretagogues like glucose or calcium. Extensive
studies have demonstrated that an increase in the cytosolic
calcium is essential for glucose-stimulated insulin release
[8]. Indeed, one of the mature, secretory forms of PTHrP,
was demonstrated by Wu et al. [9] to increase cytosolic
calcium levels in a pancreatic b-cell line (RIN 1046-38).
Increased cytosolic calcium levels have also been reported
in insulinoma cells supporting the notion that PTHrP is
not only secreted by pancreatic cells, but might also play
an autocrine or paracrine role within the islets themselves
[10]. In 2006, Shor et al. [11] evaluated the eﬀects of
both oral calcium and glucose loads on insulin and PTHrP
secretion in healthy controls. They reported that PTHrP
and insulin rose are in parallel although this response
was not observed during the calcium load. Moreover, they
found signiﬁcant diﬀerences in basal serum PTHrP levels
particularly in type 2 versus type 1 diabetics and healthy
controls.Ishidaetal.[7]proposedthatelevatedPTHrPlevels
might play a compensatory role in calcium homeostasis in
diabetic patients. They speculate that these patients often
exhibit osteopenia and lower than normal PTH levels with
a net result: the preservation of normal serum calcium
levels. Additional evidence was further obtained by the
group of Suzuki et al. [12] who found a signiﬁcant positive
correlation between calcemia and PTHrP in noninsulin-
dependent diabetic patients.
In line with the previous reports, we conﬁrmed that
PTHrP serum levels exhibited a signiﬁcant increase in
type 2 diabetes compared to control subjects. Moreover,
our data demonstrate that that PTHrP was statistically
signiﬁcantly correlated with glucose in type 2 diabetes and
in normal subjects in the fasting state. Interestingly, PTHrP
showed a positive correlation with insulin levels only among
healthy individuals presumably due to defective glucose
stimulated insulin secretion known to occur in type 2
diabetics.
In conclusion, a strong positive correlation of PTHrP has
been established with glucose in the fasting state. PTHrP
appears to be related to the presence of type 2 diabetes and
not to the patient’s obesity and hormonal status. Further
studies are needed in order to elucidate the exact role and
the physiological signiﬁcance of PTHrP in patients with type
2 diabetes mellitus.
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